CGON
CG Oncology, Inc. Common stock NASDAQ Listed Jan 25, 2024$69.17
Mkt Cap $5.8B
52w Low $21.90
91.5% of range
52w High $73.56
50d MA $65.61
200d MA $46.48
P/E (TTM)
-31.9x
EV/EBITDA
-20.0x
P/B
6.8x
Debt/Equity
0.0x
ROE
-21.4%
P/FCF
-24.2x
RSI (14)
—
ATR (14)
—
Beta
0.70
50d MA
$65.61
200d MA
$46.48
Avg Volume
1.2M
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
400 Spectrum Center Drive · Irvine, DE 75247 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | BMO | — | — | — | 69.18 | -0.4% | +0.6% | — | — | — | — | — |
| May 7, 2026 | BMO | — | — | — | 68.01 | +0.2% | +1.7% | — | — | — | — | — |
| Feb 27, 2026 | AMC | -0.61 | -0.51 | +16.4% | 58.80 | -2.9% | -1.8% | +3.0% | +4.7% | +2.7% | +5.2% | — |
| Nov 14, 2025 | AMC | -0.56 | -0.57 | -2.0% | 41.01 | +1.0% | +0.6% | +3.8% | +3.9% | -0.7% | +3.5% | — |
| Aug 8, 2025 | AMC | -0.49 | -0.54 | -10.2% | 24.85 | -0.4% | -3.6% | +0.4% | +6.6% | +4.5% | +3.4% | — |
| May 13, 2025 | AMC | -0.39 | -0.45 | -15.4% | 24.18 | -0.4% | -0.0% | +4.8% | +5.2% | +2.8% | +9.8% | — |
| Mar 28, 2025 | AMC | -0.41 | -0.48 | -17.1% | 26.42 | +1.5% | -7.3% | -16.5% | -15.8% | -29.1% | -34.9% | — |
| Aug 8, 2024 | AMC | -0.42 | -0.28 | +33.3% | 33.24 | +1.1% | +1.2% | -1.0% | +0.8% | -0.0% | +3.5% | — |
| May 9, 2024 | AMC | -0.35 | -0.36 | -2.9% | 30.02 | -0.0% | -5.1% | -13.9% | -9.0% | -6.7% | +3.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | RBC Capital | Maintains | Outperform → Outperform | — | $68.68 | $69.10 | +0.6% | -2.7% | -4.6% | -5.7% | -2.8% | -3.5% |
| Apr 17 | JP Morgan | Maintains | Overweight → Overweight | — | $66.34 | $67.61 | +1.9% | +10.7% | +6.1% | +8.3% | +5.3% | +5.4% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.55 | $68.56 | +1.5% | +3.3% | +2.0% | +1.5% | +0.2% | +0.2% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.11 | $55.79 | -0.6% | +4.8% | +2.9% | +7.9% | +9.7% | +7.6% |
| Feb 10 | Truist | Maintains | Buy → Buy | — | $51.08 | $51.37 | +0.6% | +3.9% | +4.8% | +1.1% | +0.8% | +5.5% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $54.69 | $55.03 | +0.6% | +4.5% | +2.1% | -1.6% | -2.5% | +0.7% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $53.07 | $53.20 | +0.2% | +3.1% | +3.1% | +7.7% | +5.2% | +1.4% |
| Jan 12 | Truist | Maintains | Buy → Buy | — | $54.20 | $55.31 | +2.0% | -0.9% | -3.0% | +2.4% | -2.1% | +1.0% |
| Nov 17 | RBC Capital | Maintains | Outperform → Outperform | — | $41.01 | $41.43 | +1.0% | +0.6% | +3.8% | +3.9% | -0.7% | +3.5% |
| Sep 26 | JP Morgan | Maintains | Overweight → Overweight | — | $36.48 | $37.46 | +2.7% | +2.9% | +7.1% | +10.4% | +8.2% | +9.2% |
| Sep 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $35.76 | $36.48 | +2.0% | +5.5% | +8.6% | +3.2% | +3.6% | +2.6% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.34 | $35.10 | +5.3% | +3.8% | +7.3% | +13.1% | +16.4% | +10.7% |
| Sep 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $33.07 | $33.81 | +2.2% | +1.9% | +1.2% | +1.7% | +0.3% | +0.8% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.07 | $33.81 | +2.2% | +1.9% | +1.2% | +1.7% | +0.3% | +0.8% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.94 | $31.13 | +0.6% | +6.9% | +8.9% | +8.2% | +8.7% | +7.2% |
| Jul 16 | RBC Capital | Maintains | Outperform → Outperform | — | $24.95 | $24.70 | -1.0% | +4.5% | +14.1% | +7.2% | +7.8% | +4.2% |
| Jun 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.46 | $25.67 | +0.8% | +3.1% | +3.2% | +0.4% | +0.8% | +1.3% |
| May 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.43 | $24.48 | -3.7% | -2.2% | +4.4% | +3.1% | +1.3% | +0.0% |
| Apr 29 | RBC Capital | Maintains | Outperform → Outperform | — | $27.97 | $28.26 | +1.0% | -3.7% | -3.7% | -0.8% | +3.9% | +0.8% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.37 | $31.00 | +38.6% | +25.0% | +20.4% | +20.4% | +24.0% | +29.9% |
| Apr 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.37 | $31.00 | +38.6% | +25.0% | +20.4% | +20.4% | +24.0% | +29.9% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.42 | $26.82 | +1.5% | -7.3% | -16.5% | -15.8% | -29.1% | -34.9% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.53 | $28.41 | -0.4% | -3.5% | -7.0% | -5.6% | -7.4% | -14.2% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.20 | $29.66 | -1.8% | -5.0% | -7.4% | -2.0% | -3.6% | -3.7% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.46 | $30.00 | -1.5% | -0.9% | -5.8% | -8.2% | -2.8% | -4.5% |
| Dec 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.56 | $33.86 | +0.9% | +3.1% | -1.0% | +0.4% | -5.5% | -14.0% |
| Dec 6 | RBC Capital | Maintains | Outperform → Outperform | — | $33.56 | $33.86 | +0.9% | +3.1% | -1.0% | +0.4% | -5.5% | -14.0% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.98 | $37.45 | +1.3% | -4.9% | -4.0% | -11.0% | -10.2% | -11.3% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.69 | $39.68 | -0.0% | -6.8% | -11.4% | -10.6% | -17.1% | -16.3% |
| Oct 8 | BofA Securities | Maintains | Buy → Buy | — | $35.48 | $35.42 | -0.2% | -1.9% | -2.1% | -2.8% | +1.7% | +5.7% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.00 | $37.01 | +0.0% | +2.0% | +0.2% | +5.7% | +5.4% | +3.6% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.71 | $32.99 | +0.9% | -0.9% | -0.9% | +4.8% | -0.4% | +10.1% |
| May 14 | Goldman Sachs | Upgrade | Neutral → Buy | — | $25.84 | $27.80 | +7.6% | +5.7% | +8.4% | +19.9% | +16.0% | +15.1% |
| May 13 | Goldman Sachs | Upgrade | Neutral → Buy | — | $28.50 | $29.00 | +1.8% | -9.3% | -4.1% | -1.7% | +8.7% | +5.2% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.02 | $30.01 | -0.0% | -5.1% | -13.9% | -9.0% | -6.7% | +3.2% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.27 | $37.01 | +2.0% | -3.2% | -6.4% | -10.6% | -17.2% | -21.4% |
| May 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.27 | $37.01 | +2.0% | -3.2% | -6.4% | -10.6% | -17.2% | -21.4% |
| May 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $40.62 | $41.16 | +1.3% | -2.8% | -10.7% | -13.6% | -16.4% | -20.2% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.39 | $38.65 | +0.7% | -1.7% | +0.2% | +2.0% | +1.6% | +0.3% |
No insider trades available.
8-K · 2.02
!! High
CG Oncology, Inc. -- 8-K 2.02: Earnings Results
CG Oncology reported Q1 2026 financial results, providing investors with updated operational performance and financial metrics to assess the company's progress and cash position.
May 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new executive at CGON is receiving $520,000 base salary plus 45% bonus potential, with equity grants vesting April 2026, signaling leadership continuity and standard compensation that shouldn't materially impact valuation.
Apr 13
8-K
CG Oncology, Inc. -- 8-K Filing
CG Oncology anticipates releasing interim data from its Phase III PIVOT-006 trial evaluating cretostimide for non-muscle invasive bladder cancer, a potential catalyst for investors monitoring the company's clinical pipeline progress.
Feb 27
Data updated apr 25, 2026 1:01am
· Source: massive.com